Gossamer Bio Newsroom

Gossamer Bio (GOSS) Gets a Buy From Oppenheimer

TipRanksNov 12, 2024 20:51

HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target

BenzingaNov 11, 2024 23:11

Gossamer Bio Analyst Ratings

BenzingaNov 11, 2024 23:10

Promising Progress and Expansion Potential of Gossamer Bio's Seralutinib Drive Buy Rating

TipRanksNov 11, 2024 19:23

Oppenheimer Maintains Gossamer Bio(GOSS.US) With Buy Rating, Raises Target Price to $9

Futu NewsSep 16, 2024 20:31

Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow JonesAug 30, 2024 17:52

Goldman Sachs Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $8

Futu NewsAug 14, 2024 19:31

Buy Rating Affirmed for Gossamer Bio Amidst Financial Growth and Clinical Advancements

TipRanksAug 14, 2024 18:37

Barclays Reaffirms Their Hold Rating on Gossamer Bio (GOSS)

TipRanksAug 14, 2024 15:52

Gossamer Bio Analyst Ratings

BenzingaAug 13, 2024 20:30

Wedbush Reiterates Outperform on Gossamer Bio, Maintains $4 Price Target

BenzingaAug 13, 2024 20:30

Piper Sandler Keeps Their Buy Rating on Gossamer Bio (GOSS)

TipRanksAug 13, 2024 18:54

Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)

TipRanksAug 13, 2024 18:54

Gossamer Bio (GOSS) Receives a Buy From Piper Sandler

TipRanksJul 15, 2024 18:50

Gossamer Bio Analyst Ratings

BenzingaJun 25, 2024 17:42

Oppenheimer Initiates Coverage On Gossamer Bio With Outperform Rating, Announces Price Target of $9

BenzingaJun 25, 2024 17:42

Gossamer Bio Analyst Ratings

BenzingaJun 18, 2024 00:46

Goldman Sachs Maintains Buy on Gossamer Bio, Maintains $8 Price Target

BenzingaJun 18, 2024 00:46

Buy Rating Reaffirmed for Gossamer Bio on Seralutinib's Promising Clinical Data and Future Prospects

TipRanksMay 20, 2024 23:30

HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target

BenzingaMay 20, 2024 23:15